Low-Dose Naltrexone
Ultra-low dose opioid antagonist that paradoxically enhances endorphin signaling and modulates immune function.
Evidence Summary
Low-dose naltrexone (LDN, typically 1.5–4.5 mg at bedtime) is an off-label, compounded use of the opioid antagonist naltrexone studied for chronic pain and autoimmune/inflammatory conditions. The strongest recent evidence is in fibromyalgia. A 2024 systematic review and meta-analysis with trial sequential analysis (Vatvani et al., Korean Journal of Pain 2024;37(4):367–378; 4 RCTs, 222 patients) found LDN reduced pain versus placebo (mean difference −0.86 on a 0–10 scale, 95% CI −1.20 to −0.51; p<0.001) and roughly tripled the odds of a ≥30% pain improvement (odds ratio 3.32, 95% CI 1.59–6.92), with the cumulative evidence crossing the pre-specified superiority boundary; pressure-pain threshold also improved modestly (MD 0.17, 95% CI 0.08–0.25). A separate 2025 systematic review and meta-analysis (Journal of Pain & Palliative Care Pharmacotherapy 2025;39(3), doi:10.1080/15360288.2025.2496526) reached concordant conclusions. Pooled effects on overall fibromyalgia impact (FIQR) were not statistically significant (p=0.19), so LDN is best viewed as one component of a broader plan rather than a stand-alone treatment. Mechanistically, transient opioid-receptor blockade is followed by a compensatory rise in endorphins and enkephalins, while LDN also antagonizes Toll-like receptor 4 (TLR4) on microglia, dampening pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and central sensitization. Beyond fibromyalgia, controlled and observational data suggest possible benefit in other centralized-pain and autoimmune conditions (for example Crohn's disease, multiple-sclerosis-related mood symptoms, and ME/CFS), though those evidence bases are smaller. Safety at low doses is favorable: serious adverse events were not increased versus placebo (OR 0.33, 95% CI 0.01–8.38), with vivid dreams (OR 2.97) and mild nausea (OR 2.75) the most common, usually transient, side effects. LDN must not be combined with opioid medications. Educational information only, not medical advice; use exclusively under qualified clinical supervision.
Evidence Scale
Mechanism of Action
Transient blockade of opioid receptors triggers a compensatory upregulation of endogenous endorphins and enkephalins, enhancing the body's own analgesia. In parallel, LDN antagonizes Toll-like receptor 4 (TLR4) on microglia and other glial cells, reducing microglial activation and the pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) that drive neuroinflammation and central pain sensitization.
Who Is This For?
Autoimmune conditions, chronic pain, chronic fatigue, cancer adjunct. Must avoid opioid medications.
Protocol & Dosing
Dose
1.5-4.5mg at bedtime. Start 1.5mg, titrate weekly.
Frequency
Daily at bedtime
Duration
Ongoing
Protocol Summary
Compounded oral capsule or liquid taken at bedtime. Start low (typically 1.5 mg) and titrate weekly toward 3–4.5 mg as tolerated; most fibromyalgia RCTs used 4.5 mg/day. Avoid all opioid medications while taking LDN. Consider baseline and follow-up inflammatory markers (for example hs-CRP) and a validated pain/symptom scale to track response over 8–12 weeks. Requires physician supervision and pharmacy compounding.
Latest Evidence
2024–2025: meta-analyses confirm a pain benefit in fibromyalgia
A 2024 systematic review and meta-analysis with trial sequential analysis (4 randomized trials, 222 patients) found that low-dose naltrexone reduced fibromyalgia pain versus placebo by a mean difference of −0.86 on a 0–10 scale (95% CI −1.20 to −0.51; p<0.001) and roughly tripled the odds of a ≥30% pain improvement (odds ratio 3.32, 95% CI 1.59–6.92). The cumulative evidence crossed the pre-specified superiority boundary, and a separate 2025 meta-analysis reached concordant conclusions. Effects on the overall Fibromyalgia Impact Questionnaire were not statistically significant, so LDN is best used as one component of a broader, biomarker-tracked plan.
These pooled results come from small, mostly short trials. LDN is an off-label, compounded therapy that must never be combined with opioid medications, and it does not cure fibromyalgia or replace established care. Vivid dreams and mild nausea are the most common, usually transient, side effects; serious adverse events were not increased versus placebo. Use only under qualified clinician supervision. Educational information, not medical advice.
Meta-analysis · 4 RCTs · 222 patients · 2024
LDN vs placebo in fibromyalgia: pooled odds ratios
Pooled odds ratios (LDN 4.5 mg/day vs placebo) with 95% CI; a ≥30% pain response was about 3× more likely on LDN. Vivid dreams and nausea were the most common, usually transient, side effects; serious adverse events were not increased (OR 0.33, 95% CI 0.01–8.38). Source: Vatvani et al., Korean Journal of Pain 2024;37(4):367–378.
Related on Peak Human
Optimization Service
Physician-supervised protocol management and biomarker-tracked follow-up.
Diagnostic Testing
Baseline and follow-up inflammatory markers such as hs-CRP.
Inflammatory Biomarkers
LDN targets TLR4-driven neuroinflammation — track the markers it affects.
Gut Health
LDN is studied as an adjunct in autoimmune gut conditions like Crohn's.
Brain Fog
Overlaps with the fatigue and cognitive symptoms seen in fibromyalgia and ME/CFS.
Longevity Research Insider
Dr. Goel's weekly review of new longevity and healthspan research.
Key references: Vatvani et al. — LDN for fibromyalgia: meta-analysis with trial sequential analysis, Korean J Pain (2024) · Efficacy of LDN in fibromyalgia: systematic review & meta-analysis, J Pain Palliat Care Pharmacother (2025) · LDN for non-cancer centralized pain: a scoping review, Pain Medicine (2023)
Interactions & Precautions
Contraindications
- Current opioid use
- Acute opioid withdrawal
- Hepatic failure
Potential Risks
- •Temporary sleep disruption
- •Opioid interaction
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Must avoid opioids. Vivid dreams often temporary. Consider for autoimmune conditions before stronger immunosuppressants. Cancer applications promising.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation